The effects of phentolamine, 0.3 mg/mm given intravetient and it had no effect on the HQ or HS intervals. This nopsly for 15 minutes, on atrioventricular and intravenrepresents ao improvement in conduction through the tricular conduction were studied in seven cardiac patients atrioventricular node. Phentolamine had no effect on aod in four normal subjects. Recordings were made at atrioventricular and intraventricular conduction in the varied heart rates, utilizing atrial pacing. Phentolamine four normal subjects. significantly reduced the AH interval in every cardiac pa-I n his experimental work on dogs, Leimdorfer1s2 showed that the intravenous administration of phentolamine (Regitine) prevented nicotine sulphate and epinephrine-induced arrhythmias and converted methacholine-induced atrial flutter, fibrillation and atrioventricular nodal rhythm to normal sinus rhythm. He further showed that phentolamine administration prevented the appearance of pronounced bradycardia during electrical stimulation of the vagus nerve.
The effects of phentolamine, 0.3 mg/mm given intravetient and it had no effect on the HQ or HS intervals. This nopsly for 15 minutes, on atrioventricular and intravenrepresents ao improvement in conduction through the tricular conduction were studied in seven cardiac patients atrioventricular node. Phentolamine had no effect on aod in four normal subjects. Recordings were made at atrioventricular and intraventricular conduction in the varied heart rates, utilizing atrial pacing. Phentolamine four normal subjects. significantly reduced the AH interval in every cardiac pa-I n his experimental work on dogs, Leimdorfer1s2 showed that the intravenous administration of phentolamine (Regitine) prevented nicotine sulphate and epinephrine-induced arrhythmias and converted methacholine-induced atrial flutter, fibrillation and atrioventricular nodal rhythm to normal sinus rhythm. He further showed that phentolamine administration prevented the appearance of pronounced bradycardia during electrical stimulation of the vagus nerve.
In an additional study,3 ten normal dogs were rapidly digitalized with ouabain until electrocardiographic abnormalities of rhythm occurred. Phentolamine, infused intravenously at 0.3 mglmin, rapidly abolished ventricular tachycardia in four of five cases, ventricular premature contractions in three cases, and complete heart block in one case. It increased the sinus rate in one case of sinus bradycardia.
Phentolamine has recently been used to treat cardiac arrhythmias in man.4 When the drug was infused intravenously at 0.3 mglmin to 25 patients with digitalis as well as nondigitalis-induced ventricular premature contractions, all but one responded with a decrease or an abolition in the number of extrasystoles. Similarly, intravenously administered phentolamine can effectively reduce the frequency of supraventricular premature beats. 5 Phentolamine has also been administered orally to 21 patients with persistent ventricular premature contractions. In 15 patients the ventricular prema- There are few data available on the effects of phentolamine on cardiac conduction in patients. In this study, phentolamine was administered to 11 patients. Electrocardiograms and bundle of His electrograms were recorded before and after the admin. istration of the drug. The effects on both atrioventricular and intraventricular condustion were determined.
The study group consisted of seven patients with organic heart disease and four subjects with normal hearts. The clinical features of the group are summarized in Table 1 . Patients 1 and 3 had cardiac catheterization to evaluate their murmur and chest pain, respectively. Patients 2 and 4 were studied to rule out the possibility of cor pulmonale. All patients were informed of the nature of the study and signed consent was obtained. Patients were studied in the supine position, and were in a postabsorptive, nonsedated state.
Under local anesthesia, a bipolar pacing catheter was introduced percutaneously into the right femoral vein and fluoroscopically positioned at the bicuspid valve. The position 
H-Q Intend
Tbe H-Q interval is the first rapid deflection of the His debction to the onset of the QRS deflection in the electrocnrdiogram. The H-Q interval approximates conduction in the specialized tissues of the His Purkinje system.
H-S Zntsrwl
The H-S interval is the first rapid bundle of His deflection to the end of the QRS deflection on the electrocardiogram.
Tbe HS interval approximates total intraventricular conduction time.
The PA, AH, HQ and HS intervals were recorded in all patients before pacing and at ahid pacing rates between 70 to 150 beats/min. Similar recordings were obtained before and aher the administration of phentolamine. In addition, the postpacing recovery time of the sinus node pacemaker was o b e d following sudden cessation of the highest pacing rate attained. This was accomplished before and after the pbentolamine infusion.
RESULTS

The measurements of PI-A, AH, HQ and HS in-
tervals at all paced heart rates are shown in Table 2 . Phentolamine statistically shortened the AH interval at atrial pacing rates of 100, 120 and 140 beatslmin in patients 5-12 with cardiac disease (Table 2) . However, the PI-A, HQ and HS intervals were unchanged after administration of phentolamine. A representative recording is presented in Figure 1 . During atrial pacing at a rate of 1001min the PI-A, AH, HQ and HS intervals were 80, 240, 60 and 150 msec, respectively. After the administration of phentolamine, the AH interval decreased to 200 msec, but the PI-A, HQ and HS intervals were unchanged. Second degree heart block occurred at higher pacing rates after phentolamine therapy as compared to the control state. Further, the postsuppressive sinoatrial node recovery time was diminished in most cases after the phentolamine infusion. In Table 3 , the effects of phentolamine on the AH interval in the patients with cardiac disease are tabulated. Not every patient could be tested at the varied paced rates because of the development of A-V block. However, a significant decrease in the AH interval was observed in the cardiac patients after the administration of phentolamine.
Phentolamine administration had no effect on atrioventricular and intraventricular conduction in the four patients with normal hearts.
The present study revealed that phentolamine administration produced a sigdcant reduction in the AH interval with no effect on the PI-A, HQ or HS interval, in the patients with cardiac disease. FIGURE 1. His electrogram obtained in patient five at paced atrial rate of 100 beats/min before and after phentolamine infusion. PI-A interval and AH interval prior to phentolamine therapy were 80 and 240 msec, respectively. After administration of phentolamine PI-A interval was unchanged, while AH interval decreased to UW) msec. Second degree heart block occurred at higher pacing rate after phentolamine treatment as compared to the control state. Further, the postsuppression SA node recovery time was diminished in most cases after the phentolamine infusion. In the four normal subjects, phentolamine had no demonstrable effect on the conduction system. Similarly, in a previous study from our laboratory, the administration of phentolamine to patients with cardiac disease produced a striking hemodynamic improvement.' The cardiac output, cardiac rate, systemic pressure and stroke index increased, while the pulmonary artery pressure, systemic peripheral resistance, left ventricular end diastolic pressure and left ventricular end diastolic volume fell. An infusion of phentolamine in normal subjects produced only minimal changes in the cardiac pressures and cardiac output.
This improvement in cardiac function in the patients with abnormal hearts may be explained by the recent observations of various workers. Dainnan et a18 administered phentolamine (5 mglkg) to rats.
At the height of a-receptor blockade, the conversion of a tracer dose of tyrosine"" to norepinephrine in the heart, brain, and adrenal gland was increased threefold, with no alteration in specac activity of tyrosine in blood and tissues. From these studies, Dairmans concluded that receptor blockade led to increased synthesis and release of norepinephrine in the three organs that were measured. This contention has received support from the recent work of Bagwell et al. 9 They administered 5 mglkg of phentolamine to seven experimental animals and observed an increase in the left ventricular contractile force. If the animals were pretreated with reserpine, phentolamine's inotropic action could be blocked. A subsequent infusion of norepinephrine could then restore phentolamine's inotropic effect. They9 conclude that the positive inotropic action of phentolamine is indirect and dependent on the release of norepinephrine.
It has recently been demonstrated that phentolamine has 8-adrenergic stimulating properties as well as its a-adrenergic blocking effects. This 8-adrenergic stimulating action is suggested by the observation that the fall in blood pressure and the increase in cardiac rate produced by 5 mg of phentolamine can be sigdcantly blocked by the prior administration of propranolol.1° Propranolol can similarly block the inotropic and chronotropic action of phentolamine in d0gs.l
The release of catecholamines also explains the improvement in conduction through the atrioventricular node, as shown by the shortening of the AH intervals in the present study. Phentolamine had no effect on the His Purkinje system or intraventricular conduction, as indicated by a lack of change in the HQ and HS intervals. Khan et all2 have also recently observed that phentolamine can shorten the PH interval in patients with abnormal hearts. Our work supports and extends their observations.
Rosen et alls recently studied the electrophysiologic effects of phentolamine on canine Purkinje fibers. They observe that the drug can prolong the action potential duration and the effective refractory period as well as decrease the membrane responsiveness and conduction velocity. It therefore resembles quinidine in its electrophysiologic actions.
If phentolamine can increase the availability of endogenous catecholamines to the heart, it is possible that the drug acts at least in part in a manner different from most other antiarrhythmic drugs. Catecholamines are known to cause hyperpolarization of partially depolarized or "sick fibers. The result is restoration of a normal action potential configuration without significant change in phase 4."
By this means, catecholamines may increase conduction velocity through areas where abnormal conduction is occurring, and hence abolish arrhythmias.I5 It is conceivable that at least part of the antiarrhythmic action noted with phentolamine may be secondary to such a mechanism.
